RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:KIF20B and MET, hub genes of DIAPHs, predict poor prognosis and promote pancreatic cancer progression.
KIF20B and MET, hub genes of DIAPHs, predict poor prognosis and promote pancreatic cancer progression.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
DIAPHs、KIF20B 和 MET 是 PC 预后和治疗的有前景的候选靶点。更重要的是,KIF20B 和 MET 的下调通过调控 LDHA 和 EMT 抑制了胰腺癌进展。
DIAPHs(DIAPH1、DIAPH2 和 DIAPH3)是 formin 家族 diaphanous 亚家族的成员。KIF20B 和 MET 作为 DIAPHs 的枢纽基因,在细胞骨架重塑、细胞迁移和黏附中发挥关键作用。然而,它们在胰腺腺癌(PC)中的联合预后和治疗价值有待进一步研究。
采用多组学分析工具全面评估KIF20B和MET在PC中的基因组表达及预后价值。建立并分析了免疫细胞浸润、功能富集、单细胞RNA测序(scRNA)分析、潜在治疗药物及列线图。通过CCK-8水平、transwell实验、Co-IP实验、质谱分析和western blotting评估KIF20B和MET在体外作为β-catenin和乳酸脱氢酶A(LDHA)调节因子的作用。采用异种移植肿瘤模型评估体内抗肿瘤效果。
DIAPHs、KIF20B 和 MET 在 PC 中过表达,并作为不良预后标志物发挥作用。免疫浸润分析显示,pDC 和 NK 细胞在 KIF20B 和 MET 低表达水平下富集,而 Th2 细胞在这两个基因高表达水平下富集。KIF20B 和 MET 的拷贝数变异(CNVs)与 B 细胞和 CD4 + T 细胞浸润呈正相关。免疫检查点 NT5E 和 CD44 与 KIF20B 和 MET 表达呈正相关。此外,基于 KIF20B 和 MET 构建的列线图对总生存期显示出预测价值。scRNA-Seq 分析表明,KIF20B 和 MET 在内皮细胞、恶性细胞、B 细胞、T 细胞和 CD8 + T 细胞中富集,这与糖酵解和上皮-间质转化(EMT)相关。KIF20B 和 MET 与 β-catenin 和 LDHA 的相互作用通过 Co-IP 实验和质谱分析得到验证。在体外敲低 KIF20B 和 MET 可下调 β-catenin 和 LDHA。此外,KIF20B 和 MET 的双重敲低在体外和体内对 PC 进展表现出协同抑制作用。
The DIAPHs (DIAPH1, DIAPH2, and DIAPH3) are members of the diaphanous subfamily of the formin family. KIF20B and MET, hub genes of DIAPHs, play crucial roles in cytoskeletal remodeling, cell migration, and adhesion. However, their combined prognostic and treatment value in pancreatic adenocarcinoma (PC) warrants further investigation.
Multiomics analysis tools were used to comprehensively assess the genomic expression and prognostic value of KIF20B and MET in PC. Immune cell infiltration, functional enrichment, single-cell RNA-seq (scRNA) analysis, potential therapeutic drugs, and nomograms were established and analyzed. CCK-8 levels, transwell assay, Co-IP assay, mass spectrometry, and western blotting were performed to assess the role of KIF20B and MET as modulators of β-catenin and Lactate Dehydrogenase A (LDHA) in vitro. Xenograft tumor models were used to evaluate the anti-tumor effects in vivo.
DIAPHs, KIF20B, and MET were overexpressed and functioned as poor prognostic markers of PC. Immunoinfiltration analysis revealed that pDC and NK cells were enriched with low expression levels of KIF20B and MET, whereas Th2 cells were enriched with high expression levels of these two genes. The copy number variations (CNVs) in KIF20B and MET were positively correlated with B cell and CD4 + T cell infiltration. Immunological checkpoints NT5E and CD44 were positively correlated with KIF20B and MET expression. Moreover, the nomogram constructed based on KIF20B and MET demonstrated predictive value for overall survival. scRNA-Seq analysis indicated that KIF20B and MET were enriched in endothelial, malignant, B, T, and CD8 + T cells, which correlated with glycolysis and the epithelial-mesenchymal transition (EMT). The interactions of KIF20B and MET with β-catenin and LDHA were verified by Co-IP assay and mass spectrometry. Knockdown of KIF20B and MET downregulates β-catenin and LDHA in vitro. Furthermore, dual knockdown of KIF20B and MET exhibited a synergistic suppressive effect on PC progression in vitro and in vivo.
DIAPHs, KIF20B, and MET are promising candidates for the prognosis and treatment of PC. More importantly, downregulation of KIF20B and MET inhibited pancreatic cancer progression by regulating LDHA and EMT.
MEMBER ACCOUNT
登录成功会直接打开下一页。